ConfidentialRiptide Aurinia Collaboration & License AgreementBetweenAurinia Pharmaceuticals Inc.andRiptide Bioscience, Inc. Effective Date: August 16, 2021License Agreement • August 17th, 2021 • Aurinia Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Riptide Aurinia Collaboration & License Agreement (the “Agreement”) is entered into as of August 16, 2021 (the “Effective Date”), by Aurinia Pharmaceuticals Inc., an Alberta corporation having offices at #1203-4464 Markham Street, Victoria, BC V8Z 7X8 Canada (“Aurinia”) and Riptide Bioscience, Inc., a corporation duly organized and existing under the laws of Delaware, having offices at 941 Railroad Avenue, Vallejo, California 94592 USA (“Riptide”). Both Aurinia and Riptide are referred to individually as a “Party” and collectively as the “Parties.”
